Pharmaceuticals News and Research

RSS

Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

Derma Sciences, Inc., a tissue regeneration and burn care company focused on advanced wound care, today reported financial and operating results for the three months and year ended December 31, 2013.

14 Mar 2014

Researcher discover new chemical class that attacks two key cancer cell building block targets

Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

14 Mar 2014

Bruker releases application note for detection of pharmaceutical and personal care products in water using EVOQ LC-MS/MS

Bruker has released an application note detailing a simple and convenient method for the quantification of trace pharmaceutical and personal care products (PPCPs) in clean water, using Bruker’s EVOQ triple quadrupole liquid chromatography mass spectrometer (LC-MS/MS). PPCPs are products used for personal health or cosmetic reasons.

13 Mar 2014

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn.

13 Mar 2014

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

SAGE Therapeutics announces completion of $38 million Series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing. OrbiMed Advisors, LLC, EcoR1 Capital Management, Foresite Capital Management and two undisclosed blue chip public investment funds joined existing investors Third Rock Ventures and ARCH Venture Partners.

13 Mar 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Risk, pregnancy and childbirth

New research published in a special issue of Health, Risk & Society looks at perceptions of risk around pregnancy and how this influences decisions about where to give birth. Despite childbirth in the UK being increasingly considered safe, the article by Kirstie Coxon and colleagues show that childbirth is still seen as 'risky'.

13 Mar 2014

New research raises hopes of new class of drugs to combat antibiotic resistant infections

New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections

13 Mar 2014

CRO services division of Galapagos to be acquired by Charles River Laboratories

Charles River Laboratories International, Inc. announced today that it has entered into a definitive agreement to acquire the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus.

13 Mar 2014

Galmed Pharmaceuticals prices initial public offering of 2,837,400 shares

Galmed Pharmaceuticals Ltd. ("Galmed") today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions.

13 Mar 2014

Perrigo launches methazolamide tablets

Perrigo Company today announced that it has launched, through a distribution and supply agreement, methazolamide tablets, the generic equivalent to Neptazane tablets. This product is a component of the contingent rights Perrigo received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals, LLC and its affiliates in June of last year.

12 Mar 2014

Protein Metrics releases Byologic software to improve analytical quality

Protein Metrics, Inc., a leading provider of software for rapid and thorough protein characterization, today announced the release of Byologic. Byologic software enables easy and convenient identification and quantification of sequence variants, protein modifications, and degradants down to trace concentrations.

12 Mar 2014

EPFL sets up foundation to release antibiotic for tuberculosis

Even though tuberculosis kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.

12 Mar 2014

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).

12 Mar 2014

GE announces winners of the GE Healthcare 2013 Cell Imaging Competition

GE Healthcare Life Sciences (NYSE:GE) today announced Vanessa Auld from Canada, Martin Barr from Ireland and Graham Wright from Singapore as the winners of the GE Healthcare 2013 Cell Imaging Competition.

12 Mar 2014

MEDIAN Technologies inks €700K deal with leading pharmaceutical company

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced it has signed a contract with a global top five pharmaceutical company.

12 Mar 2014

CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

In March 2012, the 1st Nextgen China was held successfully in Shanghai. FDA, USP, national institutes for Food and Drug Control and leading pharmaceutical companies from home and abroad were invited to give presentations.

12 Mar 2014

Monash University research offers new hope to people with heart attacks

Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects.

11 Mar 2014